Relay Therapeutics, Inc. leads with RLY-2608, an allosteric PI3Kα inhibitor showing superior safety & efficacy. Learn more ...
New research reveals how tiny electrical gates in the brain, known as NMDA receptors, control learning, memory, and neuron ...
News Medical on MSN
AI Revolutionizes Solid Tumor Drug Development
Artificial intelligence (AI) is fundamentally reshaping the landscape of solid tumor (ST) drug development. By integrating multi-omics data, spatial ...
Neuphoria Therapeutics Inc. ("Neuphoria" or the "Company") (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments ...
Neuphoria Therapeutics Inc. ('Neuphoria” or the 'Company”) (Nasdaq: NEUP), a clinical-stage biotechnology company developing impactful treatments for neuropsychiatric disorders, today announced that ...
Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced preliminary clinical and preclinical ...
Seventh paragraph, second sentence of release issued October 24, 2025, should read: "a disease control rate (DCR) of 83%" ...
Sudo Biosciences, ("Sudo"), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, today announced positive topline results from ...
BMS Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback